Article Text

PDF
Journal club summaries
What's hot that the other lot got
  1. Kathryn Prior
  1. Correspondence to Dr Kathryn Prior, Torbay Hospital, South Devon Healthcare NHS Foundation Trust, Newton Rd, Torquay, Devon TQ2 7AA, UK; Kathrynbrain{at}doctors.net.uk

Statistics from Altmetric.com

Which combination inhaler should we use for COPD?

3362 patients with at least one exacerbation of COPD in the previous year were randomised to a long acting β agonist Indacaterol (LABA) and a Long acting muscarinic agonist (LAMA) Glycopyrronium or LABA Salmeterol and inhaled glucocorticoid fluticasone (doi: 10.1056/NEJMoa1516385). The outcome was annual rate of COPD exacerbation. In the LABA-LAMA group there was an 11% reduction in the exacerbation rate (3.59 vs 4.03; rate ratio, 0.89; 95% CI, 0.83 to 0.96; p=0.003) with comparison to the LABA-steroid group. There was also a longer time to first exacerbation (71 days (95% CI 60 to 82) vs 51 days (95% CI 46 to 57); HR, 0.84 (95% CI 0.78 to 0.91), representing a 16% lower risk; p<0.001). The annual rate of severe exacerbations was lower (0.98 vs 1.19; rate ratio, 0.83; 95% CI 0.75 to 0.91; p<0.001). The exacerbation rate was independent of the blood eosinophil count. The incidence of pneumonia was 3.2% in the LABA-LAMA group and 4.8% in the LABA steroid group (p=0.02).

Dupilumab for asthma

Dupilumab is a fully human anti-interleukin-4 receptor α monoclonal antibody, which inhibits interleukin-4 and interleukin-13 signalling, these are drivers …

View Full Text

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.